戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 uent diagnoses were ocular toxoplasmosis and cytomegalovirus retinitis.
2 ction therapy and the time to progression of cytomegalovirus retinitis.
3 rimary outcome we studied was progression of cytomegalovirus retinitis.
4 f 188 patients with AIDS and newly diagnosed cytomegalovirus retinitis.
5 on, 18 months after the initial diagnosis of Cytomegalovirus retinitis.
6 fective local therapy for AIDS patients with cytomegalovirus retinitis.
7 acrimal obstruction, herpetic keratitis, and cytomegalovirus retinitis.
8 ed risk for Cytomegalovirus disease, notably Cytomegalovirus retinitis.
9 ents: 2 Pneumocystis carinii pneumonia and 1 cytomegalovirus retinitis.
10 n, which have received FDA approval to treat cytomegalovirus retinitis and high blood cholesterol, re
11       The proportion of ADIs attributable to cytomegalovirus retinitis and Mycobacterium avium comple
12 stem cell transplantation and a case each of cytomegalovirus retinitis and pneumonitis.
13 homa control, infectious corneal ulceration, cytomegalovirus retinitis, and retinopathy of prematurit
14 tial pneumonitis, systemic fungal infection, cytomegalovirus retinitis, and tuberculosis were all les
15 nformation about patients who develop active cytomegalovirus retinitis as an immune reconstitution in
16                             The treatment of cytomegalovirus retinitis (CMV-R) has improved considera
17 munodeficiency syndrome (AIDS) patients with Cytomegalovirus retinitis (CMVR) -related retinal detach
18                    Advances in management of cytomegalovirus retinitis (CMVR) include laser demarcati
19 relates of immune recovery from AIDS-related cytomegalovirus retinitis (CMVR), multiparameter flow cy
20                                              Cytomegalovirus retinitis could be prevented by improved
21 ia, Mycobacterium avium complex disease, and cytomegalovirus retinitis) declined from 21.9 per 100 pe
22 ganciclovir (9.9 percent) had progression of cytomegalovirus retinitis during the first four weeks (d
23 as administered as the initial treatment for cytomegalovirus retinitis (group A); 17 eyes had previou
24 vir as induction therapy for newly diagnosed cytomegalovirus retinitis in 160 patients with the acqui
25 of belatacept-associated multidrug-resistant Cytomegalovirus retinitis in a kidney transplant recipie
26  cells may also be involved in modulation of cytomegalovirus retinitis in human patients.
27 ll subsets might be used to treat or prevent cytomegalovirus retinitis in immunosuppressed human pati
28 nd effective for the long-term management of cytomegalovirus retinitis in patients with AIDS.
29  implant is effective for local treatment of cytomegalovirus retinitis in patients with the acquired
30 e an alternative method for the treatment of cytomegalovirus retinitis in patients with the acquired
31  oral candidiasis, IR, 1.2; 95% CI, 1.0-1.5; cytomegalovirus retinitis, IR, 0.5; 95% CI, 0.3-0.6; and
32                                              Cytomegalovirus retinitis is a serious infection because
33                                              Cytomegalovirus retinitis is an uncommon opportunistic i
34                                              Cytomegalovirus retinitis is associated with a high abso
35                                              Cytomegalovirus retinitis is usually diagnosed clinicall
36                            The occurrence of Cytomegalovirus retinitis may help improve the selection
37                    In patients with AIDS and cytomegalovirus retinitis, oral ganciclovir in conjuncti
38                                              Cytomegalovirus retinitis remains a major cause of illne
39  of HIV-associated ocular disease, including cytomegalovirus retinitis, the leading cause of vision l
40                                        Human cytomegalovirus retinitis, the most common ophthalmic in
41                         For the treatment of cytomegalovirus retinitis, the sustained-release gancicl
42 irus (HIV)-infected patients with concurrent cytomegalovirus retinitis were divided into three groups
43 enty-seven patients with AIDS and unilateral cytomegalovirus retinitis were randomly assigned to one
44      Treatment and subsequent maintenance of cytomegalovirus retinitis with 20 micrograms of intravit
45  eyes of patients who received treatment for cytomegalovirus retinitis with either a ganciclovir impl
46                      Treatment of unilateral cytomegalovirus retinitis with systemic ganciclovir decr
47 s photographically determined progression of cytomegalovirus retinitis within four weeks after the in